|
Non-Small Cell Lung Carcinoma
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
We therefore propose the expression level of MMS19 as a candidate predictive marker of ACT benefit in resected NSCLC patients.
|
27802208 |
2016 |
|
Osteosarcoma
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
Our findings showed polymorphisms in ERCC5 rs1047768 and MMS19L rs29001322 to be associated with clinical outcome of osteosarcoma patients undergoing chemotherapy.
|
23679317 |
2013 |
|
Osteosarcoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
XPG and MMS19L are correlated with response to chemotherapy and prognosis of osteosarcoma, so that they could be used as predictive markers for prognosis.
|
23886164 |
2013 |
|
Osteosarcoma of bone
|
0.020 |
Biomarker
|
disease |
BEFREE |
XPG and MMS19L are correlated with response to chemotherapy and prognosis of osteosarcoma, so that they could be used as predictive markers for prognosis.
|
23886164 |
2013 |
|
Osteosarcoma of bone
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
Our findings showed polymorphisms in ERCC5 rs1047768 and MMS19L rs29001322 to be associated with clinical outcome of osteosarcoma patients undergoing chemotherapy.
|
23679317 |
2013 |
|
Childhood Osteosarcoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
XPG and MMS19L are correlated with response to chemotherapy and prognosis of osteosarcoma, so that they could be used as predictive markers for prognosis.
|
23886164 |
2013 |
|
Childhood Osteosarcoma
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
Our findings showed polymorphisms in ERCC5 rs1047768 and MMS19L rs29001322 to be associated with clinical outcome of osteosarcoma patients undergoing chemotherapy.
|
23679317 |
2013 |
|
Non-Small Cell Lung Carcinoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
MMS19L might be associated with the adverse events of chemotherapy in NSCLC, especially for all grade leucopenia (P = 0.020), all grade jaundice (P = 0.037) and all grade creatinine increasing (P = 0.013).
|
23118991 |
2012 |
|
Malignant Neoplasms
|
0.010 |
AlteredExpression
|
group |
BEFREE |
Thus, flux through the CIA pathway can be regulated by degradation of the substrate-specifying MMS19 protein and its downregulation is a common feature in cancer and is evolutionarily controlled.
|
29225034 |
2018 |
|
Primary malignant neoplasm
|
0.010 |
AlteredExpression
|
group |
BEFREE |
Thus, flux through the CIA pathway can be regulated by degradation of the substrate-specifying MMS19 protein and its downregulation is a common feature in cancer and is evolutionarily controlled.
|
29225034 |
2018 |
|
Malignant neoplasm of prostate
|
0.010 |
Biomarker
|
disease |
BEFREE |
We aimed to investigate the association between genetic variants of the DNA repair genes XPG, CSB, XPC, CCNH, and MMS19L in the nucleotide excision repair (NER) pathway and risk of prostate cancer in a population in China.
|
24615090 |
2014 |
|
Prostate carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
We aimed to investigate the association between genetic variants of the DNA repair genes XPG, CSB, XPC, CCNH, and MMS19L in the nucleotide excision repair (NER) pathway and risk of prostate cancer in a population in China.
|
24615090 |
2014 |
|
Neoplasms
|
0.010 |
Biomarker
|
group |
BEFREE |
This study aims to assess the role of polymorphisms in DNA repair genes, excision repair cross-complementation group 1 (ERCC1) and methyl-methanesulfonate sensitivity 19 (MMS19), in tumor response to platinum-based chemotherapy and survival in advanced epithelial ovarian cancer (EOC).
|
23632208 |
2013 |
|
Epithelial ovarian cancer
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
The role of single nucleotide polymorphisms of the ERCC1 and MMS19 genes in predicting platinum-sensitivity, progression-free and overall survival in advanced epithelial ovarian cancer.
|
23632208 |
2013 |
|
Carcinoma, Ovarian Epithelial
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
The role of single nucleotide polymorphisms of the ERCC1 and MMS19 genes in predicting platinum-sensitivity, progression-free and overall survival in advanced epithelial ovarian cancer.
|
23632208 |
2013 |
|
Icterus
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
MMS19L might be associated with the adverse events of chemotherapy in NSCLC, especially for all grade leucopenia (P = 0.020), all grade jaundice (P = 0.037) and all grade creatinine increasing (P = 0.013).
|
23118991 |
2012 |
|
Leukopenia
|
0.010 |
Biomarker
|
disease |
BEFREE |
MMS19L might be associated with the adverse events of chemotherapy in NSCLC, especially for all grade leucopenia (P = 0.020), all grade jaundice (P = 0.037) and all grade creatinine increasing (P = 0.013).
|
23118991 |
2012 |
|
Thrombocytopenia
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
In terms of grade 3/4 adverse events, MMS19L was related with total grade 3/4 adverse events (P = 0.024) and grade 3/4 thrombocytopenia (P = 0.035), while RRM1 was related with total grade 3/4 adverse events (P = 0.047) and grade 3/4 vomiting (P = 0.046).
|
23118991 |
2012 |
|
Vomiting
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
In terms of grade 3/4 adverse events, MMS19L was related with total grade 3/4 adverse events (P = 0.024) and grade 3/4 thrombocytopenia (P = 0.035), while RRM1 was related with total grade 3/4 adverse events (P = 0.047) and grade 3/4 vomiting (P = 0.046).
|
23118991 |
2012 |
|
Xeroderma Pigmentosum, Complementation Group D
|
0.010 |
Biomarker
|
disease |
BEFREE |
However, the MMS19-XPD complex did not contain any other subunits of TFIIH.
|
20797633 |
2010 |
|
Pancreatic carcinoma
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Gene level analyses showed an association of the MMS19L genotype (chromosome 10q24.1) with altered pancreatic cancer risk (P = 0.023).
|
19318433 |
2009 |
|
Malignant neoplasm of pancreas
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Gene level analyses showed an association of the MMS19L genotype (chromosome 10q24.1) with altered pancreatic cancer risk (P = 0.023).
|
19318433 |
2009 |